Adam Baker, director of science at Chr. Hansen, discussed recent in-house clinical trials observing an amplified response following administration of probiotics with HMOs, compared with pre- or probiotics given alone, at Probiota last week.
A systematic review of dozens of studies has revealed that levels of the five most prevalent HMOs in breast milk vary widely, and infant formula development should accommodate this variability.
A recent analysis has found that the global infant formula ingredients market is expanding steadily with the rising middle class and the demand for high-quality infant formula gains traction.
